AKBA Stock Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Notes are coming soon
Akebia Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.63|
|52 Week High||US$2.93|
|52 Week Low||US$0.24|
|1 Month Change||9.19%|
|3 Month Change||120.98%|
|1 Year Change||-66.31%|
|3 Year Change||-92.35%|
|5 Year Change||-95.61%|
|Change since IPO||-97.64%|
Recent News & Updates
Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging HigherAug 10
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?Jun 24
Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?May 26
Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?Mar 31
Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?Mar 10
Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?Mar 10
Does Akebia Therapeutics (NASDAQ:AKBA) Have A Healthy Balance Sheet?Nov 28
|AKBA||US Biotechs||US Market|
Return vs Industry: AKBA underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: AKBA underperformed the US Market which returned -13.6% over the past year.
|AKBA Average Weekly Movement||13.2%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: AKBA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AKBA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Akebia Therapeutics, Inc. Fundamentals Summary
|AKBA fundamental statistics|
Is AKBA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AKBA income statement (TTM)|
|Cost of Revenue||US$213.82m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.85|
|Net Profit Margin||-52.42%|
How did AKBA perform over the long term?See historical performance and comparison